Healixia is the Belgian community of all professionals active along the life cycle of medicines, medical devices, in vitro diagnostics & other health related products. Members are active in research & development (including pre-clinical, early clinical and later phases), medical affairs, safety, regulatory affairs and market access in industry, academia, investigator sites, authorities, regulatory bodies or in consultancy.

Become a member

Healixia events

  1. beatriz-perez-moya-XN4T2PVUUgk-unsplash.jpg
    18 October '22

    Webinar: The sources of life sciences regulations - part II: Medicinal products


    This session is the second part of a two-part training course on the “Sources of life sciences regulation”. It serves to provide participants with a high-level overview of the rules and regulations applicable to medicinal products for human use in the European Union. The session will include a specific part on the Belgian legislation. It will also provide the audience with practical tips on researching applicable laws.

  2. agenda items (5).jpg
    27 October '22

    Healixia Essentials: the role and impact of the MSL (Medical Science Liaison) explained.


    The how, the why and the who: all you would like to know about the MSL (Medical Science Liaison). This webinar is aimed at life science professionals who are not very familiar with this role or who would like to learn more on it.

  3. agenda items (5).jpg
    01 December '22

    Healixia Essentials: How does pharma.be defend the interests of the innovative pharma industry in Belgium?


    Face-to-face lunchmeeting.

    pharma.be is the voice of the innovative Belgian - human and veterinary medicine - pharmaceutical industry. As interest group it represents 130 both small and large innovative pharmaceutical and biotech companies and is the centre of excellence for the industry.

    Come and learn more on how exactly pharma.be works to defend the interests of the pharma industry in Belgium and take the opportunity to meet your peers.

Show all meetings


  1. October 7, 2022

    PRAC October 2022 – New measures for terlipressin-containing medicines and change to product information for combination of medicines with codeine and ibuprofen

    During its October 2022 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has recommended new measures for terlipressin-containing medicines and has also recommended a change to the product information for codeine with ibuprofen combination medicines. The PRAC also discussed direct healthcare professional communications (DHPCs) containing important safety information for terlipressin-containing medicines and Imbruvica.

    Source: FAMHP

    Read more

  2. October 7, 2022

    Amended legislation: drug precursors added to list of scheduled substances

    The European Commission's new Delegated Regulation (EU) 2022/1518 adds two drug precursors to the list of scheduled substances. The regulation entered into force on 3 October 2022.

    Source: FAMHP

    Read more

  3. October 6, 2022

    IFAPP Today newsletter - October 2022

    Source: IFAPP

    Please find here the link to the IFAPP TODAY newsletter of October 2022.

    Read more

We thank our partners for their support:

AxTalis_reg access medical_scherm_transparent Brookwood Global-website QbD Group Logo_blue Janssen 440x320 nieuwsbrief